2,6-dichloro-4-iodotoluene | 177167-52-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,6-dichloro-4-iodotoluene
• 英文别名: 1,3-Dichloro-5-iodo-2-methylbenzene
• CAS: 177167-52-1
• 化学式: C₇H₅Cl₂I
• 分子量: 286.927
• InChiKey: RIQUEWZYAUZWRN-UHFFFAOYSA-N

物化性质

• 沸点：
  273.8±35.0 °C(Predicted)
• 密度：
  1.891±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  2,6-dichloro-4-iodotoluene 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 16.0h， 以75%的产率得到2,6-dichloro-4-iodobenzyl bromide
  参考文献：
  名称：

  Banfi, Stefano; Manfredi, Amedea; Pozz, Gianluca, Gazzetta chimica Italiana, 1996, vol. 126, # 3, p. 179 - 185

  摘要：

  DOI：
• 作为产物：
  描述：

  3,5-二氯-4-甲基苯胺 在 对甲苯磺酸 、 potassium iodide 、 sodium nitrite 作用下， 以 乙腈 、 水 为溶剂， 反应 1.17h， 以67%的产率得到2,6-dichloro-4-iodotoluene
  参考文献：
  名称：

  Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7)

  摘要：

  Here, we report the discovery of a new class of NPBWR1 antagonists identified from a fragment-based screen. Compound 1 (cAMP IC₅₀ = 250 µM; LE = 0.29) emerged as an initial hit. Further optimization of 1 by SAR-by-catalogue and chemical modification produced 21a (cAMP IC₅₀ = 30 nM; LE = 0.39) with a 6700-fold increase in potency from fragment 1. Somewhat surprisingly, Schild analysis of compound 21a suggested that in vitro inhibition of NPW-mediated effects on upon cAMP accumulation were saturable, and that compound 21a dose-dependently increased [125I]-hNPW23 dissociation rate constants from NPBWR1 in kinetic binding studies. Collectively, these data are inconsistent with a classic surmountable, orthosteric mechanism of inhibition. The benzimidazole inhibitors reported herein may therefore represent a mechanistically differentiated class of compounds with which to form a better appreciation of the pharmacology and physiological roles of this central neuropeptide system.

  DOI：

  10.1016/j.bmcl.2020.127510

文献信息

• BORON-CONTAINING SMALL MOLECULES
  申请人：Eli Lilly and Company

  公开号：US20130131016A1

  公开（公告）日：2013-05-23

  This invention provides novel compounds, methods of using the compounds, and pharmaceutical formulations comprising the compounds.

  这项发明提供了新颖的化合物，使用这些化合物的方法，以及包含这些化合物的药物配方。
• Proton Mobility in 2-Substituted 1,3-Dichlorobenzenes: “ortho” or “meta” Metalation?
  作者：Manfred Schlosser、Christophe Heiss、Elena Marzi、Rosario Scopelliti

  DOI：10.1002/ejoc.200600350

  日期：2006.10

  Nine 1,3-dichlorobenzene congeners were selected as model compds. to assess the relative rates of proton abstraction from 4- and 5-positions ("ortho" vs. "meta" metalation). Using lithium 2,2,6,6-tetramethylpiperidide as the basic reagent, the chlorine-adjacent 4-position underwent metalation exclusively. In contrast, attack at the chlorine-remote 5-position became significant even in the case of moderately

  选择九个 1,3-二氯苯同系物作为模型化合物。评估从 4 位和 5 位（“邻位”与“元”金属化）提取质子的相对速率。使用 2,2,6,6-四甲基哌啶锂作为碱性试剂，4 位氯附近专门进行金属化。相比之下，当使用仲丁基锂时，即使在中等大小的 2-取代基（如二甲氨基或乙基）的情况下，对氯远程 5-位的攻击也变得显着。“邻位/对位”(4-/5-) 比率范围为 80:20 至 65:35。与碳取代基相反，硅更显着的“元取向”效应可归因于芳族的 pi 极化的不同。戒指。[在 SciFinder (R) 上]
• JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
  申请人：GOODACRE SIMON CHARLES

  公开号：US20100317643A1

  公开（公告）日：2010-12-16

  The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R 1 , R 2 , R 4 and R 5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof

  这项发明提供了公式I的化合物，其立体异构体或药学上可接受的盐，其中A、B、D、R1、R2、R4和R5在此处被定义，包括公式I化合物的药物组合物以及其使用方法
• Sterically Controlled Iodination of Arenes via Iridium-Catalyzed C–H Borylation
  作者：Benjamin M. Partridge、John F. Hartwig

  DOI：10.1021/ol303164h

  日期：2013.1.4

  to prepare aryl and heteroaryl iodides by sequential C–H borylation and iodination is reported. The regioselectivity of this process is controlled by steric effects on the C–H borylation step and is complementary to existing methods to form aryl iodides. The iodination of boronic esters has potential for the synthesis of radiolabeled aryl iodides, as demonstrated by the concise synthesis of a potential

  报道了一种通过连续的C–H硼化和碘化制备芳基和杂芳基碘化物的温和方法。该过程的区域选择性由C–H硼化步骤中的空间效应控制，是对现有形成芳基碘化物的方法的补充。硼酸酯的碘化具有放射性标记的芳基碘化物的合成潜力，正如SPECT成像的潜在示踪剂的简明合成所证明的那样。
• Boron containing small molecules
  申请人：Eli Lilly and Company

  公开号：US08853186B2

  公开（公告）日：2014-10-07

  This invention provides novel compounds, methods of using the compounds, and pharmaceutical formulations comprising the compounds.

  该发明提供了新型化合物，使用该化合物的方法以及包含该化合物的制药配方。